サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468398

前立腺がん治療市場レポート：薬剤タイプ、流通チャネル、地域別、2024～2032年

Prostate Cancer Treatment Market Report by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 138 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
前立腺がん治療市場レポート：薬剤タイプ、流通チャネル、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の前立腺がん治療市場規模は2023年に77億米ドルに達しました。今後、IMARC Groupは、2024～2032年の間に5.1%の成長率（CAGR）を示し、2032年までに121億米ドルに達すると予測しています。

前立腺がんは重篤な悪性腫瘍の一種であり、男性に存在する前立腺の様々な異常細胞の制御不能な分裂と拡大によって引き起こされます。ワクチン、薬剤療法、治療法などの様々な治療法を用いて治療することができます。その中でも、化学療法、免疫療法、凍結療法、手術療法、ホルモン療法、標的療法、放射線療法は、体内のがん細胞の広がりを抑えるのに役立つ最も一般的な治療法です。これらの治療法は、患者の年齢、経験した症状の重症度、病状、過去の健康歴など、様々な評価に基づいて患者に提供されます。

前立腺がん治療市場の動向：

前立腺がんの有病率の増加、特に高齢者人口の増加が、現在市場を成長へと向かわせる主要要因の1つです。これに伴い、患者支援プログラム（PAP）導入に向けた有利な医療償還政策の利用可能性や、数カ国の政府機関による数多くの取り組みが、他の成長促進要因として作用しています。PAPは製薬会社によって管理される組織的なプログラムで、治療目的の薬を無料で提供することによって患者に経済的支援を記載しています。さらに、マルチパラメトリック磁気共鳴画像法（mp-MRI）装置と非転移性去勢抵抗性前立腺がん（nmCRPC）と転移性ホルモン転移性前立腺がん（mHNPC）の設定との統合など、診断ミスを軽減しながら前立腺がんを早期段階で検出するための著しい技術進歩も、市場の成長に寄与しています。さらに、新規治療製品を導入するための研究開発（R&D）活動への広範な投資と、さまざまなオンライン・オフライン流通チャネルでの容易な入手が、市場に明るい展望を生み出しています。

本レポートで扱う主要質問

  • 2023年の世界の前立腺がん治療市場規模は？
  • 2024～2032年の世界の前立腺がん治療市場の予想成長率は？
  • 前立腺がん治療の世界市場を牽引する主要因は何か？
  • COVID-19が前立腺がん治療の世界市場に与えた影響は？
  • 前立腺がん治療の世界市場における薬剤タイプ別の区分は？
  • 流通チャネル別の前立腺がん治療の世界市場の内訳は？
  • 前立腺がん治療の世界市場における主要地域は？
  • 前立腺がん治療の世界市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 前立腺がん治療の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤タイプ別

  • 化学療法
  • 生物学的療法
  • ホルモン療法
  • その他

第7章 市場内訳：流通チャネル別

  • 病院薬局
  • ドラッグストア・薬局
  • オンライン薬局

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Bayer Aktiengesellschaft
    • Dendreon Pharmaceuticals LLC.（Sanpower Group Co. Ltd.）
    • F. Hoffmann-La Roche AG
    • Ferring B.V.
    • GlaxoSmithKline Plc
    • Ipsen（Mayroy SA）
    • Novartis International AG
    • Takeda Pharmaceutical Company Ltd.
    • Tolmar Pharmaceuticals Inc.
図表

List of Figures

  • Figure 1: Global: Prostate Cancer Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Prostate Cancer Treatment Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Prostate Cancer Treatment Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Prostate Cancer Treatment Market: Breakup by Drug Type (in %), 2023
  • Figure 5: Global: Prostate Cancer Treatment Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Prostate Cancer Treatment Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Prostate Cancer Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Prostate Cancer Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Prostate Cancer Treatment (Biological Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Prostate Cancer Treatment (Biological Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Prostate Cancer Treatment (Hormone Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Prostate Cancer Treatment (Hormone Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Prostate Cancer Treatment (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Prostate Cancer Treatment (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Prostate Cancer Treatment (Hospitals Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Prostate Cancer Treatment (Hospitals Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Prostate Cancer Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Prostate Cancer Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Prostate Cancer Treatment (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Prostate Cancer Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: North America: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: North America: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: United States: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: United States: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Canada: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Canada: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Asia-Pacific: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Asia-Pacific: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: China: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: China: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Japan: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Japan: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: India: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: India: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: South Korea: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: South Korea: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Australia: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Australia: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Indonesia: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Indonesia: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Others: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Others: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Europe: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Europe: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Germany: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Germany: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: France: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: France: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: United Kingdom: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: United Kingdom: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Italy: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Italy: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Spain: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Spain: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Russia: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Russia: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Latin America: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Latin America: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Brazil: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Brazil: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Mexico: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Mexico: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Middle East and Africa: Prostate Cancer Treatment Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Middle East and Africa: Prostate Cancer Treatment Market: Breakup by Country (in %), 2023
  • Figure 69: Middle East and Africa: Prostate Cancer Treatment Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Global: Prostate Cancer Treatment Industry: SWOT Analysis
  • Figure 71: Global: Prostate Cancer Treatment Industry: Value Chain Analysis
  • Figure 72: Global: Prostate Cancer Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Prostate Cancer Treatment Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Prostate Cancer Treatment Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Prostate Cancer Treatment Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Prostate Cancer Treatment Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Prostate Cancer Treatment Market: Competitive Structure
  • Table 6: Global: Prostate Cancer Treatment Market: Key Players
目次
Product Code: SR112024A6185

The global prostate cancer treatment market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032.

Prostate cancer is a type of severe malignant tumor, which is caused by the uncontrollable division and expansion of various abnormal cells in the prostate gland present in men. It can be treated through the use of various therapeutics, such as vaccines, medications, and treatments. Amongst these, chemotherapy, immunotherapy, cryotherapy, surgery, hormonal, targeted and radiation therapy are some of the most common treatment types that aid in mitigating the spread of cancer cells in the body. These therapies are provided to the patient based on various assessments, such as the age of the patient, severity of the symptoms experienced, medical condition, and previous health history.

Prostate Cancer Treatment Market Trends:

The increasing prevalence of prostate cancer, especially amongst the rising geriatric population, is one of the prime factors currently driving the market toward growth. In line with this, the availability of favorable medical reimbursement policies and the numerous initiatives being undertaken by the government bodies of several countries for introducing patient assistance programs (PAPs) are acting as other growth-inducing factors. PAP is an organized program, which is controlled by pharmaceutical companies for providing financial assistance to patients by offering free medications for treatment purposes. Moreover, significant technological advancements, such as the integration of multiparametric-magnetic resonance imaging (mp-MRI) devices with non-metastatic castration-resistant (nmCRPC) and metastatic hormone nave (mHNPC) settings for detecting prostate cancer at early stages, while mitigating diagnostic errors, is also contributing to the market growth. Additionally, extensive investments in the research and development (R&D) activities to introduce novel therapeutic products, along with their easy availability across various online and offline distribution channels, are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global prostate cancer treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug type and distribution channel.

Breakup by Drug Type:

Chemotherapy

Biological Therapy

Hormone Therapy

Others

Breakup by Distribution Channel:

Hospitals Pharmacies

Drug Stores and Retail Pharmacies

Online Pharmacies

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., AstraZeneca plc, Bayer Aktiengesellschaft, Dendreon Pharmaceuticals LLC. (Sanpower Group Co. Ltd.), F. Hoffmann-La Roche AG, Ferring B.V., GlaxoSmithKline Plc, Ipsen (Mayroy SA), Novartis International AG, Takeda Pharmaceutical Company Ltd. and Tolmar Pharmaceuticals Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global prostate cancer treatment market in 2023?
  • 2. What is the expected growth rate of the global prostate cancer treatment market during 2024-2032?
  • 3. What are the key factors driving the global prostate cancer treatment market?
  • 4. What has been the impact of COVID-19 on the global prostate cancer treatment market?
  • 5. What is the breakup of the global prostate cancer treatment market based on drug type?
  • 6. What is the breakup of the global prostate cancer treatment market based on the distribution channel?
  • 7. What are the key regions in the global prostate cancer treatment market?
  • 8. Who are the key players/companies in the global prostate cancer treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Prostate Cancer Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Biological Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hormone Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospitals Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Drug Stores and Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Astellas Pharma Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer Aktiengesellschaft
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Dendreon Pharmaceuticals LLC. (Sanpower Group Co. Ltd.)
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 F. Hoffmann-La Roche AG
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Ferring B.V.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
    • 13.3.7 GlaxoSmithKline Plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Ipsen (Mayroy SA)
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Novartis International AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Takeda Pharmaceutical Company Ltd.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Tolmar Pharmaceuticals Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio